Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Yabing Cao
Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients
PLoS ONE
Multidisciplinary
Related publications
P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer
European Journal of Cancer
Cancer Research
Oncology
A Case Report of an EML4-ALK-positive Elderly Non-Small Cell Lung Cancer Patient With a Poor PS Successfully Treated With Crizotinib
Japanese Journal of Lung Cancer
Oncology
Respiratory Medicine
Pulmonary
EMT Is Associated With, but Does Not Drive Resistance to ALK Inhibitors Among EML4-ALK Non-Small Cell Lung Cancer
Molecular Oncology
Cancer Research
Medicine
Oncology
Genetics
Molecular Medicine
